Skip to Main Content

Paper Details

PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.
PLoS Pathog
30
2021

Datasets

Release 1.2